HOME >> BIOLOGY >> NEWS
IC-medtech licenses promising cancer therapeutic from Summa Health System

(Akron, Ohio) In September 2001, researchers at Summa Health System in Akron, Ohio reported that moderate doses of the vitamins C and K3 were eliminating many types of cancer cells including prostate, bladder, renal and ovarian. Today, only three years later, the results of Summa's cancer research is being licensed and under a new name, ApatoneTM. Clinical trials of the drug could begin as soon as next month at Summa Health System and other hospitals across the nation.

Indian Creek Medical Technologies, LLC has exclusively licensed Apatone, the novel anti-cancer therapeutic treatment first discovered by James M. Jamison, Ph.D. and Jack L. Summers, M.D, Ph.D, both of Summa Health System, in collaboration with Jacques Gilloteaux, DSc, and Henryk Taper, M.D., Ph.D. of Brussels, Belgium. The Summa team has been working collaboratively with Gilloteaux and Taper for nine years conducting extensive experimentation and now Summers and Jamison are excited by this next step with IC-MedTech.

"What is so significant about our study is that through out research of cancer cells, we have discovered a new form of cell death, never before reported," said Summers.

"We found early on that the combination of vitamins C and K3 seek out tumor cells and appear to leave normal cells unaffected," Summers explained. "The dying cells undergo a new flow of self-destruction in which the cell literally cuts itself into small pieces. This discovery was the first of its kind and to this point, cells were considered to die only by apoptosis (programmed cell death) or necrosis (toxic cell death or injury.)"

According to Tom Miller, CEO of IC-MedTech, his company is excited about the possibilities this drug could bring to cancer patients. "The research is substantial and shows that Apatone leverages a novel mechanism of action that shows strong promise as a clinical candidate to be developed for a variety of cancers."


'"/>

Contact: Heather Phillips
philliph@summa-health.org
330-375-7930
Summa Health System
26-Oct-2004


Page: 1 2

Related biology news :

1. University of Colorado licenses two influenza virus detection discoveries to Quidel Corp.
2. Rensselaer licenses microscope technology to Thorlabs
3. Columbia University licenses next-generation DNA sequencing technology
4. Case Western Reserve University licenses methoxyamine to Tracon
5. Yale licenses potential anti-HIV agent to Oncolys BioPharma of Japan
6. Mount Sinai School of Medicine licenses avian flu vaccine to Avimex
7. Bayer HealthCare licenses Genomatix for microarray analysis
8. Isotron licenses ORNL cancer treatment technology
9. A new plant-bacterial symbiotic mechanism promising
10. A new plant-bacterial symbiotic mechanism promising for crop applications
11. American Association for Cancer Research provides support for promising cancer scientists

Post Your Comments:
(Date:4/16/2014)... store memories improves during childhood, associated with structural ... prefrontal and parietal cortices. New research from UC ... at this crucial time. Eventually, that could give ... transition into and during adolescence and affect memory, ... in the middle of the brain, the hippocampus ...
(Date:4/16/2014)... Dr. Klaus Aktories and Dr. Panagiotis Papatheodorou from the ... the University of Freiburg have discovered the receptor responsible ... perfringens into the cell. The TpeL toxin, which ... that causes gas gangrene and food poisoning. It is ... germs of the genus Clostridium . The toxins ...
(Date:4/15/2014)... 15, 2014, Irvine, Calif. UC Irvine neurobiologists have ... results when transplanted into the brains of mice with ... trial is published in the journal Stem Cells ... shown to work in two different mouse models. ... of dementia, is associated with accumulation of the protein ...
Breaking Biology News(10 mins):How kids' brain structures grow as memory develops 2Gate for bacterial toxins found 2UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
Cached News: